Why the study?
What are the mechanisms underlying the therapeutic efficacy and off-target toxicities (particularly cardiotoxicity) of doxorubicin?
What are the mechanisms underlying the therapeutic efficacy and off-target toxicities (particularly cardiotoxicity) of doxorubicin?
Doxorubicin is a highly effective chemotherapeutic agent whose clinical use is frequently complicated by severe off-target effects, most notably cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Doxorubicin cardiotoxicity continues to limit oncology use; leaves open targeted mitigation strategies pending mechanistic studies.
Carvalho et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: